论文部分内容阅读
目的观察GDP方案对复发难治性非霍奇金淋巴瘤(NHL)的临床效果和毒副反应。方法吉西他滨(GEM)1000 mg/m2静脉滴注,第1,8天;顺铂(DDP)25 mg/m2静脉滴注,第1～3天;地塞米松(DXM)20～40 mg静脉滴注,第1～3天。每21天为1个治疗周期,化疗2个周期后评价疗效。结果本组13例患者均可作近期疗效评价。CR 5例(38.5%)、PR 4例(30.8%)、SD 2例(15.4%)、PD2例(15.4%)。总有效率(CR+PR)为69.3%。化疗细胞学不良反应主要为不同程度的骨髓抑制、脱发、恶心、呕吐、但可耐受,少数患者出现轻度的肝功能损伤,经对症治疗后缓解,不影响化疗的正常进行。结论 GDP方案治疗复发难治性NHL近期疗效有较好,且毒副反应小,能耐受,值得临床研究和推广使用。
Objective To observe the clinical effects and adverse reactions of GDP regimen in relapsed and refractory non-Hodgkin’s lymphoma (NHL). METHODS Gemcitabine (GEM) was administered intravenously at 1000 mg / m2 on days 1 and 8; intravenous infusion of 25 mg / m2 cisplatin (DDP) on day 1 to 3; intravenous drip of dexamethasone (DXM) 20 to 40 mg Note, the first 1 to 3 days. Every 21 days for a treatment cycle, chemotherapy 2 cycles after the evaluation of efficacy. Results The group of 13 patients can be used for short-term efficacy evaluation. CR 5 cases (38.5%), PR 4 cases (30.8%), SD 2 cases (15.4%) and PD 2 cases (15.4%). The total effective rate (CR + PR) was 69.3%. Chemotherapy cytology adverse reactions mainly to varying degrees of bone marrow suppression, hair loss, nausea, vomiting, but tolerable, a small number of patients with mild liver damage, symptomatic treatment after remission, does not affect the normal chemotherapy. Conclusions The GDP regimen has good curative effect in refractory relapsed and refractory NHL with less toxic and side effects and is worth of clinical research and promotion.